Objective: We evaluated the separate and interactive associations of menopausal stage, menopausal symptoms, and human immunodeficiency virus (HIV) infection with cognition. We hypothesized that HIV-infected perimenopausal women would show the greatest cognitive difficulties and that menopausal symptoms would be inversely associated with cognition.
A pproximately 52% of persons living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in the United States are aged 40 to 54 years 1 ; for women, this coincides with the menopausal transition. Despite a growing literature on normative changes in cognition, depression, and anxiety associated with the menopausal transition, little is known about menopause in HIV-infected women, particularly with regard to cognitive function. Previous cross-sectional studies indicated that, compared with HIV-uninfected women, HIV-infected women report more menopausal symptoms, including vasomotor symptoms, sleep disturbances, and psychological symptoms, 2<5 and may have an earlier age at menopause. 3, 4, 6, 7 In the United States, smoking, low socioeconomic status, and drug use are relatively common among women with HIV; these are all factors associated with depressive, anxiety, and vasomotor symptoms. 8, 9 No study has yet focused on the effects of menopausal stage and menopausal symptoms on cognition in HIVinfected women. Determining how reproductive aging might impact cognitive function in HIV is important because (1) most HIV-infected individuals worldwide are female 10 ; (2) with HIV therapies, HIV-infected individuals now survive to middle and older age; (3) menopausal stage and symptoms impact cognition in healthy women 11 ; (4) cognitive impairment is associated with specific functional deficits (eg, nonadherence to treatment regimen) in HIV-infected individuals 12 ; and (5) menopause-related cognitive issues might require new therapeutic approaches to HIV care.
Findings from large-scale, longitudinal cohort studies in healthy women suggest that menopause-associated cognitive deficits are modest, limited to the perimenopausal stage, and rebound to normal in postmenopause. Specifically, perimenopausal women demonstrate greater cognitive impairment across time compared with premenopausal women. 11, 13, 14 For example, in the Study of Women's Health Across the Nation (SWAN), the largest ongoing multisite, community-based cohort study in the United States (n = 1,903-2,362), perimenopausal, but not postmenopausal, women demonstrated greater impairment in processing speed and verbal memory than premenopausal women. 11, 14 Cross-sectional studies have also been conducted but have yielded disparate results possibly due to differences in menopausal staging criteria and cognitive test batteries.
Two general mechanisms have been postulated to contribute to cognitive changes in the menopausal transition. First, cognitive performance may reflect alterations in the function of brain structures and circuits due to changes in sex steroid hormones. Both animal and human studies indicate that the hippocampus and prefrontal cortexVbrain regions necessary for cognitive abilities such as verbal learning and memoryV are influenced by estrogen. 15<17 Second, cognitive changes may be caused by indirect effects of menopausal symptoms, including sleep disturbances and mood, anxiety, and/or vasomotor symptoms. 18, 19 Thus, the extent of cognitive changes during perimenopause may depend on symptom severity. Conversely, data from SWAN indicated that menopausal symptoms did not account for the finding that perimenopausal women were impaired on cognitive performance compared with premenopausal women. 11 In SWAN, cognition was associated with anxiety and depressive symptoms but not with sleep disturbances or vasomotor symptoms.
The purpose of this study was to examine associations between cognition, menopausal stage, and menopausal symptoms including mood, anxiety, and vasomotor symptoms, and sleep disturbances in HIV-infected and HIV-uninfected women from the Women's Interagency HIV Study (WIHS). Our first hypothesis was that there would be greater cognitive difficulties on measures of processing speed and verbal memory in perimenopausal women compared with premenopausal women. Our second hypothesis was that severity of menopausal symptoms would be inversely associated with cognitive performance. Specifically, consistent with SWAN, 11 we predicted that depressive symptoms would be negatively associated with processing speed, whereas anxiety symptoms would be negatively associated with verbal memory. We also anticipated that sleep disturbances and vasomotor symptoms would be associated with worse overall cognitive performance, and that the magnitude of these associations would be greater for HIVinfected women than for HIV-uninfected women.
METHODS

Study population
All participants were enrolled at six sites in the WIHS (Chicago, Bronx, Brooklyn, San Francisco, Los Angeles, and Washington, DC), a national multisite study of women with HIV and women at risk for HIV. Study methodology, standardized data collection, and training of interviewers have been previously reported. 20, 21 Briefly, study visits are conducted every 6 months and include a detailed survey, brief physical examination, and specimen collection. This study was approved by the institutional review boards of all participating institutions and by the WIHS Executive Committee, with a written informed consent form provided by all participants. Analyses included WIHS participants who completed cognitive testing and survey measures of menopause and mood as part of their core assessment visits.
Overall, 1,901 women were assessed for some WIHSrelated outcomes and not necessarily for cognition during WIHS visit 25 (April 2007 to April 2008). Of those women, 1,329 met all of the following inclusion criteria: (a) valid and complete data on the Hopkins Verbal Learning TestV Revised (HVLT-R; n = 349 excluded); (b) valid and complete data on menstrual cycle characteristics needed to stage menopause (n = 254 excluded); (c) valid and complete data on the SWAN menopausal symptom questionnaire (n = 224 excluded); (d) aged 30 to 65 years (n = 203 excluded); and (e) valid and complete data on the Center for Epidemiologic Studies Depression Scale (n = 22 excluded). Of the 1,329 women who met the inclusion criteria (73% of the overall sample), 343 were excluded from data analyses based on the following exclusion criteria: (a) primary language other than English (n = 12); (b) history of stroke/cerebrovascular accident (n = 18); (c) use of antipsychotic medication in the past 6 months (n = 63); (d) currently pregnant or breastfeeding (n = 8); (e) hysterectomy/bilateral oophorectomy (n = 164); and/or (f) use of hormone therapy/oral contraceptives within the past 6 months (n = 117). In BResults,[ we compare the characteristics of the women included in the analysis (n = 986) and those who were excluded (n = 912).
Measures
Neuropsychological outcome measures
Participants completed the HVLT-R (primary outcome measure) and the Comalli Stroop test. The HVLT-R is a 12-item list-learning test used to measure verbal episodic memory. 22, 23 The HVLT-R includes three learning trials, a delayed-recall trial (20-to 25-min delay), and a yes/no delayed-recognition trial. Outcomes include total words recalled on trial 1 (single trial learning), total words recalled across each of three learning trials (total learning), learning slope across the three trials (mean number of new words recalled across trials), number of words recalled after a 25-minute delay (delayed recall), and number of words correctly identified on a yes/no recognition test (recognition). Recognition scores are calculated by subtracting the number of false-positives (incorrectly responding Byes[ to a word not presented) from the number of hits (correctly responding Byes[ to a word that was presented). The Comalli Stroop test includes three trials 24 in which trials 1 and 2 measure attention and processing speed and trial 3 measures response inhibition/executive function. In trial 1, participants name the colors of a series of squares; in trial 2, they read a series of color names printed in black ink. In trial 3, participants name the color of the ink but ignore the word (eg, When shown the word Bred[ printed in blue ink, say Bblue[ rather than Bred[). 24 Completion times for all three trials are recorded. Outcomes include the mean scores on trials 1 and 2 (r = 0.67, P G 0.001) and trial 3. All outcomes were right-skewed and therefore log-transformed. This was the first administration of the HVLT-R; the Stroop test was administered previously to some participants (G1%, no exposure; 57%, one exposure; 40%, two exposures; 2%, three exposures).
Primary predictors
Menopausal stage. Questions pertaining to menopausal stage were administered during the interview. Responses were used to classify menopausal stage according to definitions used in SWAN, enabling us to compare our findings with those from SWAN. 25<28 Menopausal stages were defined as follows: premenopausal (menses in the past 3 mo with no change in regularity); early perimenopausal (menses in the past 3 mo with change in regularity); late perimenopausal (no menses within the past 3 mo but some menstrual bleeding within the past 12 mo); and postmenopausal (no menses within the past 12 mo). Depressive and anxiety symptoms. Anxiety symptoms were ascertained using a questionnaire from SWAN. 11,29<31 Participants reported the frequency of four anxiety symptoms (irritability/ grouchiness, feeling tense/nervous, pounding/racing heart, and feeling fearful for no reason) during the past 2 weeks on a scale from 1 (Bnot at all[; coded 0) to 5 (Bevery day[; coded 4). The anxiety score was the sum of the four symptom ratings. 11,29<32 Anxiety symptoms were categorized as elevated when scores were 7 or higher, consistent with SWAN. 11 Items were considered elevated if the symptom was experienced on 6 days or more in the past 2 weeks. Depressive symptoms were assessed by the Center for Epidemiologic Studies Depression Scale, 33 a 20-item self-report measure of depressive symptoms during the past week. Depressive symptoms were considered elevated when they exceeded the scale's established clinical cutoff of 16 or higher. Vasomotor symptoms and sleep disturbances. The frequency of three types of vasomotor symptoms (hot flashes, night sweats, and cold sweats) during the previous 2 weeks was recorded as follows: not at all, 1 to 5 days, 6 to 8 days, 9 to 13 days, or daily. Each of the three types of vasomotor symptoms was considered elevated if it occurred on 6 days or more per week. 11 Overall vasomotor symptoms were categorized as elevated when women reported experiencing one or more of the three types of vasomotor symptoms as elevated. Given the high prevalence of sleep disturbances in our population, 34 sleep disturbances were considered elevated if two or more of the following symptoms were reported for three or more nights per week: trouble falling asleep, waking up during the night, and waking up early.
Covariates
Sociodemographic variables and risk factors for cognitive impairment were selected based on previous literature 14,35<43 and included the following: annual household income of US$12,000 or less; positive hepatitis C virus (HCV) infection (indicated by the presence of serum antibodies to HCV); recent self-reported use (within 6 mo) of marijuana, crack, cocaine, and/or heroin; smoking; heavy alcohol use (97 drinks/wk or Q4 drinks in one sitting) 43 ; antidepressant medication use; past hormone therapy use (96 mo ago); and study site (of six sites). Age, length of education, and race/ethnicity were covariates in a normative-based regression approach to each cognitive outcome (described below). Additional HIV-related clinical variables were combination antiretroviral therapy (cART) use (no cART therapy, cART therapy + G95% adherence, or cART therapy + Q95% adherence); CD4 count lower than 200 cells/mm 3 ; HIV viral load higher than 10,000 cp/mL; CD4 nadir lower than 200 cells/mm 3 ; and duration of antiretroviral therapy use.
Statistical analysis
Differences in demographic characteristics between HIVinfected and HIV-uninfected women were examined using independent-sample t tests for continuous variables and W 2 tests for categorical variables. A series of multivariable logistic regressions were conducted to assess and validate the influence of menopausal stage on menopausal symptoms adjusting for confounders shown to impact menopausal symptoms in prior studies, including HIV status; age; race/ethnicity; education; marijuana use; crack, cocaine, and/or heroin use; smoking; heavy alcohol use; antidepressant medication use; past hormone therapy use; HCV infection; income; and study site. There were no interactions between HIV status and menopausal stage.
In the absence of published cognitive test norms for lowincome minority women, we followed Heaton et al 44 and prior work within the WIHS, 38 using a regression approach to estimate expected levels of function for the total sample based on scores of the comparison group (HIV j women), by regressing age, years of education, race/ethnicity, and the Wide Range Achievement TestVReading, a measure of reading ability 45 and a proxy for educational quality, 46 on each cognitive outcome. Next, the resulting unstandardized A weights, constants, and standard errors were used to calculate predicted scores for each test that were then subtracted from each woman's actual score and transformed to more interpretable scores (mean [SD], 50 [10] ) that had the advantage of being the same across all cognitive outcomes. In the total sample, we used multivariable regression analyses to examine the separate and interactive effects of our three independent variables of interest: HIV infection group, menopausal stage, and menopausal symptoms (depressive, anxiety, and vasomotor symptoms, and sleep disturbances). The model adjusted for confounders shown in prior studies to affect cognition, including marijuana use; crack, cocaine, and/or heroin use; smoking; alcohol use; antidepressant medication use; past hormone therapy use; HCV infection; income; and study site. We also adjusted for the number of prior exposures to the Stroop test, although they were not significantly associated with Stroop performance (P's 9 0.14). Interactions were retained in the final model (P's G 0.10); only HIV status Â anxiety was significant at P G 0.05. For significant interactions, the final model was rerun for HIV-infected women and included additional HIV-specific covariates (recent CD4 count and viral load, CD4 nadir, cART use, and adherence). All P values were two sided, with significance set to P G 0.05. P 9 0.05 and P G 0.10 were considered trends. Analyses were performed using SAS (version 9.2; SAS Institute Inc, Cary, NC).
RESULTS
Sample characteristics
Recent illicit substance use was reported significantly more frequently by HIV-uninfected women than by HIVinfected women, as were recent smoking, and heavy alcohol use ( Table 1) . HIV-infected women were older, less likely to report being Hispanic, and more likely to be HCV-positive and use antidepressant medications. All other differences were not significant. At the time of cognitive assessment, SWAN staging indicated that 56% (n = 550) of participants were premenopausal, 16% (n = 158) of participants were early perimenopausal, 5% (n = 46) of participants were late perimenopausal, and 24% (n = 232) of participants were postmenopausal. As expected based on age distribution, a larger proportion of HIV-uninfected women were premenopausal, whereas there was a larger percentage of HIV-infected post-menopausal women (P's G 0.05). The prevalence of sleep disturbances and depressive, anxiety, and vasomotor symptoms ranged between 9% and 35% ( Table 2 ). There was a trend for HIV-infected women to report more sleep disturbances compared with HIV-uninfected women (P = 0.07).
Compared with the 912 women excluded from this analysis (see BStudy Population[), the 986 women included in the analysis were more likely to be older (44.1 vs 41.2 y, P G 0.001); more likely to be more educated (12.4 vs 11.4 y, P G 0.001); more likely to be black non-Hispanic (64% vs 51%, P G 0.001); more likely to smoke (47% vs 40%, P = 0.002); more likely to recently use crack, cocaine, and/or heroin (12% vs 8%, P = 0.002); more likely to be HCVpositive (29% vs 24%, P = 0.01); and less likely to have an annual income of US$12,000 or less (48% vs 53%, P = 0.02).
Validation of mood, sleep, and anxiety as menopausal symptoms
In multivariable analyses, early perimenopausal women were more likely to report depressive and anxiety symptoms than premenopausal women (P's G 0.05; Table 3 ). Postmenopausal women were more likely to report sleep disturbances and depressive symptoms than premenopausal women (P's G 0.05). Table 2 shows unadjusted neuropsychological test scores as a function of HIV status, and Table 4 shows unadjusted scores as a function of menopausal stage. In multivariable analyses, HIV-infected women demonstrated significantly worse function than HIV-uninfected women on all outcomes (P's G 0.05; difference of È0.20 SD units; Table 5 ). The cognitive differences observed between HIV-infected and HIV-uninfected women were equivalent to the differences observed in midlife women who were 5 years different in age. 23 Menopausal stage was not significantly associated with any of the cognitive outcomes on the HVLT-R (P's 9 0.06; see Table 5 for trends). Depressive and anxiety symptoms were inversely associated with cognition (P's G 0.05). Specifically, women with elevated depressive symptoms performed worse than women without elevated depressive symptoms on all but one HVLT-R outcomeVlearning slope (difference of È0.20 SD units). Women with elevated anxiety symptoms also performed worse than women without elevated anxiety symptoms on all but one HVLT-R outcomeVtrial 1 learning (difference of È0.30 SD units). Notably, anxiety symptoms interacted with HIV status to significantly influence trial 1, learning slope, and total learning (Table 5, Fig.) . Among the HIV-infected women, those with elevated anxiety symptoms performed significantly worse than those without elevated anxiety symptoms on verbal learning outcomes (P's G 0.05). The cognitive differences observed between HIV-infected women with and without elevated anxiety symptoms were equivalent to differences observed in midlife women who were 20 years different in age. 23 In contrast, among the HIVuninfected women, there were no significant differences in cognitive performance between individuals with and without elevated anxiety symptoms. There were no significant interactions between menopausal stage or additional menopausal symptoms (depressive, vasomotor, and sleep symptoms) and HIV status on any cognitive outcome.
Hopkins Verbal Learning TestVRevised
In multivariable analyses limited to HIV-infected women, elevated anxiety symptoms were significantly associated with trial 1 (B = j3.37, SE = 1.38, P = 0.01), total learning (B = j4.40, SE = 1.42, P = 0.002), and learning slope (B = j4.31, SE = 1.57, P = 0.006) even after controlling for HIV morbidity indicators. Analyses focused on individual anxiety items indicated that feeling tense/nervous was significantly associated with worse performance on total learning (B = j3.50, SE = 1.22, P = 0.004) and trend in learning slope (B = j2.70, SE = 1.41, P = 0.05). Greater feelings of fearfulness for no reason were also significantly associated with learning slope (B = j4.50, SE = 1.87, P = 0.01).
Stroop test
HIV infection was associated with diminished performance on Stroop trials 1 and 2 and trial 3 ( Table 5 ). Menopausal stage was not significantly associated with any Stroop outcome The National Institute on Alcohol Abuse and AlcoholismYrecommended limits for women are no more than three drinks per day and no more than seven drinks per week. Heavy alcohol use refers to amounts in excess of these limits, more than seven drinks per week, or four drinks or more in one sitting.
(P's 9 0.08; see Table 5 for trends). Depressive symptoms, but not anxiety symptoms, were associated with worse performance on each Stroop outcome (P's G 0.05; difference of È0.20 SD units). Elevated vasomotor symptoms were associated with slower performance only on Stroop trials 1 and 2 (P G 0.05; difference of 0.25 SD units; see Table 5 for trend in Stroop trial 3). This association was driven by hot flashes (B = j2.75, SE = 1.25, P = 0.03) and not night sweats. There were no significant interactions between menopausal stage or menopausal symptoms and HIV status on the Stroop test.
DISCUSSION
This study examined associations between menopausal stage or menopausal symptoms and performance on measures of verbal memory, processing speed, and response inhibition in HIV-infected and HIV-uninfected women. We found no support for our first hypothesis that menopausal stage would be associated with worse performance on the cognitive domains of processing speed and verbal memory. We did, however, find support for our second hypothesis that menopausal symptoms would be related to worse cognitive performance. Specifically, after adjusting for HIV status, depressive, anxiety, and vasomotor symptoms were each independently associated with worse cognitive performance. We also found some support for our third hypothesis that menopausal symptoms would differentially be associated with cognitive performance in HIVinfected women. Specifically, there was an interaction between HIV status and anxiety such that the association between elevated anxiety and worse verbal learning was only evident in HIV-infected women and remained significant even after adjusting for HIV-related clinical indicators.
In contrast to previous studies, we found no evidence that cognitive performance, particularly on the domains of processing speed and verbal memory, was lowered in the perimenopausal stage. At least two general factors might have contributed to the lack of an association between cognition and menopausal stage in the present study. First is the crosssectional design of this investigation. Cross-sectional analyses revealed no significant association between menopausal stage and cognitive performance in SWAN, 47 whereas longitudinal analyses showed significant associations. 11 Second, sociodemographic and mental health factors might have obscured an effect of menopausal stage on WIHS participants. Most women in the WIHS are HIV-infected African Americans with annual incomes below US$12,000. Therefore, compared with SWAN, the WIHS cohort is less healthy, more economically disadvantaged, less educated, and more often drug-abusing. Similarly, the prevalence of elevated depressive symptoms was 35% in the WIHS versus 23% in SWAN. The negative effect of sociodemographic factors and depressive symptoms on cognition may have obscured any smaller effect of menopausal stage.
Menopausal symptoms (vasomotor, depressive, and anxiety symptoms) were associated with lowered cognitive function across HIV-infected and HIV-uninfected women in the WIHS. Vasomotor symptoms were related to slower processing speed on simple processing tasks requiring reading words aloud and identifying the color of blocks. Simple processing speed predicts driving behaviors and medication adherence in HIV-infected individuals, although the magnitude of the association of vasomotor symptoms with simple processing speed was small in this study. Thus, the clinical significance of the effect is likely to be minimal given that the mean t score is 50, the mean t score for women with elevated vasomotor symptoms was 47.7, and the mean t score for those reporting no elevated vasomotor symptoms was 50. 12, 48 Simple processing speed was not measured in SWAN, but both SWAN and the WIHS found no association between performance on a more complex measure of processing speed (Digit Symbol Modalities Test) and vasomotor symptoms. Depressive symptoms in WIHS participants were associated with decreased verbal memory, simple processing speed, and executive function. SWAN similarly found that depressive symptoms were negatively associated with processing speed 11 ; however, other studies have not reported an influence of depressive symptoms on cognition. 49 Consistent with SWAN, anxiety symptoms in WIHS participants were associated with lower verbal learning. 11 Among all of the symptoms investigated in this study, only anxiety was found to have a stronger association with lowered cognitive performance in HIV-infected compared with HIVuninfected women, and this association was evident on measures of verbal learning. Notably, of all symptoms measured, anxiety had the largest association with cognitive performance across participants, and the magnitude of the association between anxiety and cognition was generally greater than the magnitude of the association between HIV and cognition. The test of the interaction between HIV status and anxiety symptoms (high vs low) on verbal memory revealed a significant association only among HIV-infected women, suggesting that the effects on the combined group were driven largely by the HIV-infected women. It is not the case that the association between elevated anxiety and cognition is due to a high prevalence of anxiety symptoms in the WIHS. In fact, elevated anxiety symptoms were less prevalent in the WIHS (9%) than in SWAN (È30%). Although the low rates of anxiety in the WIHS may be surprising, studies of HIVinfected individuals show that African Americans are at lower risk for anxiety and other psychiatric disorders compared with other ethnicities 50<52 perhaps owing to reporting biases. One possible mechanism linking anxiety to decreased verbal memory in HIV-infected women is a female vulnerability to the negative effects of stress hormones on verbal memory. For example, in a community-based study of older adults, 12-hour free cortisol excretion was associated with poorer delayed verbal recall in women, but not in men. 53 Moreover, increases in cortisol during a 2.5-year period were associated with declines in memory in women, but not in men. 53 In studies involving laboratory-induced stress, stressinduced increases in cortisol levels correlated negatively with memory in women, but not in men. 54 Our study has several limitations. First, the cross-sectional design limited our ability to detect an effect of menopausal stage on cognition. The cross-sectional design also precluded FIG. Association between greater anxiety symptom severity and worse performance on verbal learning outcomes on the HVLT-R is evident in HIVinfected women but not in HIV-uninfected women. There was a significant interaction between anxiety symptoms and HIV status on trial 1 learning (P G 0.05), learning slope (P G 0.05), and total learning (P G 0.01). Among HIV-infected women, individuals with elevated anxiety symptoms performed worse than those without elevated anxiety symptoms on trial 1 learning (P G 0.05), learning slope (P = 0.01), and total learning (P G 0.001). All models were adjusted for site; depressive symptoms; vasomotor symptoms; sleep disturbances; crack, cocaine, and/or heroin use; marijuana use; smoking; heavy alcohol use; antidepressant medication use; past hormone therapy use; hepatitis C virus status; and income. *P G 0.05. HVLT-R, Hopkins Verbal Learning TestVRevised; HIV, human immunodeficiency virus. the possibility of examining causality. We presumed that anxiety and depressive symptoms led to decreased cognitive functioning; however, it is possible that cognitive difficulties may have preceded anxiety and depressive symptoms for at least some women. A longitudinal investigation is underway in the WIHS. Second, elevated anxiety symptoms were measured using a widely used menopause symptom inventory rather than a validated anxiety inventory. However, we used the same anxiety measure and cutoff as SWAN, allowing for comparisons with the largest investigation of menopausal stage and symptoms on cognition. 11 Other studies also showed that the anxiety scale used in this study is highly correlated with the Generalized Anxiety Disorder-7 scale (Spearman r = 0.71). 32 Third, although depressive and anxiety symptoms increased during the menopausal transition in this study, these symptoms were not menopause-specific. Nevertheless, these symptoms were elevated in perimenopause and related to cognition in general. 11 Depressive symptoms have been shown in a WIHS substudy to double the odds of cognitive impairment. 40 Fourth, only two cognitive tests were administered; thus, we could not evaluate associations across a broader spectrum of cognitive domains. Notably, however, we did include a test of verbal memory, a cognitive domain previously shown to be particularly sensitive to menopausal symptoms and stage. 55 CONCLUSIONS At a general level, the present results extend the findings from cohort studies of more economically advantaged women to a sample of economically disadvantaged women with a high prevalence of HIV. Our findings suggest that elevated depressive, anxiety, and vasomotor symptoms are associated with lower cognitive function in HIV-infected and HIV-uninfected women. All three symptoms are elevated in perimenopause. Anxiety is differentially associated with worse verbal learning in HIV-infected women only. Our results suggest that screening and treating anxiety symptoms in HIV-infected women might confer benefits to cognitive functions that are negatively impacted by HIV. Longitudinal studies of the menopausal transition and menopause-associated affective symptoms, using a more comprehensive cognitive test battery, are underway.
